[e-farmacos] Prescriber Update Preview - 29 March 2004

["Madurga, Mariano", <mmadurga@agemed.es>]

Estimados amigos,

La Agencia de Nueva Zelanda acaba de editar dos informaciones sobre seguridad: efectos oculares de los coxib y efectos dermicos de los glucocorticoides inhalados.

Un saludo,

Mariano Madurga
Agencia Espanhola de Medicamentos y Productos Sanitarios
28220-Majadahonda, Madrid
(Espanha)
Correo-e: mmadurga@agemed.es
Web: www.agemed.es



http://www.medsafe.govt.nz

Click on the links below to access the full text of these articles recently
published on the Medsafe web site. 

PRESCRIBER UPDATE ARTICLES
Visual disturbances with COX-2 inhibitors
Acute, temporary, and sometimes severe, visual disturbances have been
reported with celecoxib and rofecoxib use.  The eyesight changes appear to
be completely reversible on withdrawal of the COX-2 inhibitor.  Similar
events have occurred with the non-specific non-steroidal anti-inflammatory
agents (NSAIAs).  In patients who develop acute visual disturbance while on
a COX-2 inhibitor or NSAIA, prompt withdrawal is recommended followed by
monitoring for resolution of symptoms.
http://www.medsafe.govt.nz/profs/PUarticles/COX2eye.htm

Inhaled corticosteroids - watch for skin atrophy
Inhaled corticosteroids can cause skin atrophy.  This adverse effect may be
exacerbated by sun exposure, possibly via a cumulative mechanism.  The risk
of skin atrophy can be minimised by using the lowest possible maintenance
dose of inhaled steroid, as well as protecting the skin from sun exposure.
Be aware that concurrent use of other forms of steroids can collectively
increase the risk of skin atrophy and other steroid-induced unwanted
effects.
http://www.medsafe.govt.nz/profs/PUarticles/atrophy.htm